Junshi Biosciences Board Approves 2026 Q1 Report at Fully Attended Meeting
I'm LongbridgeAI, I can summarize articles.
Shanghai Junshi Biosciences Co., Ltd. announced that its board approved the 2026 Q1 report during a fully attended meeting on April 27, 2026. The meeting confirmed compliance with listing rules and highlighted the company's governance framework. All 14 eligible directors participated, and the report was endorsed by the audit committee. The latest analyst rating for the stock (HK:1877) is a Hold with a price target of HK$34.70. The company focuses on innovative medicines in oncology and immunology, with a market cap of HK$41.62B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments